Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2026
Leukapheresis, rasburicase, and acute complications of hyperleukocytosis in pediatric leukemia: A retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kesici Selman, Nakip Ozlem Saritas, Aksu Tekin, Unal Sule, Aytac Selin, Bayrakci Benan
Аннотация
INTRODUCTION: Hyperleukocytosis is associated with inferior clinical outcomes and early mortality. Leukapheresis provides a rapid reduction in the cell mass, which can cause complications known as leukostasis. This study evaluated the impact of leukapheresis versus standard medical therapy on acute short-term complications, specifically tumor lysis syndrome (TLS) and acute kidney injury (AKI).
METHODS: This single-center retrospective cohort study included 50 pediatric patients with hyperleukocytosis, admitted to the pediatric intensive care unit (PICU) between 2008 and 2023. Patients were grouped according to treatment exposure(standard therapy vs. therapeutic leukapheresis). Data collected included patient demographics, clinical and laboratory data, treatment modalities, and outcomes.
RESULTS: The incidence of TLS and AKI was similar between groups. After multivariable adjustment, leukapheresis was not independently associated with either AKI or TLS. Rasburicase administration emerged as a strong independent protective factor against TLS (OR: 0.057, 95% CI: 0.010-0.310, p = 0.001). Furthermore, TLS was identified as a major independent risk factor for AKI (OR: 28.81, 95% CI:3.779-219.697, p = 0.001). Crude overall mortality was higher in the leukapheresis group (44%) than in the standard-therapy group (16%)(p = 0.046). However, the leukapheresis group also had higher admission WBC counts, lower platelet counts, and older age, findings consistent with confounding by indication. The leukapheresis group also had longer PICU stays and a higher incidence of hypocalcemia and other complications.
CONCLUSIONS: In this retrospective cohort, leukapheresis effectively reduced the white blood cells but was not independently associated with a lower incidence of TLS or AKI.The higher crude mortality in the leukapheresis arm likely reflects baseline disease severity rather than a direct treatment effect.
METHODS: This single-center retrospective cohort study included 50 pediatric patients with hyperleukocytosis, admitted to the pediatric intensive care unit (PICU) between 2008 and 2023. Patients were grouped according to treatment exposure(standard therapy vs. therapeutic leukapheresis). Data collected included patient demographics, clinical and laboratory data, treatment modalities, and outcomes.
RESULTS: The incidence of TLS and AKI was similar between groups. After multivariable adjustment, leukapheresis was not independently associated with either AKI or TLS. Rasburicase administration emerged as a strong independent protective factor against TLS (OR: 0.057, 95% CI: 0.010-0.310, p = 0.001). Furthermore, TLS was identified as a major independent risk factor for AKI (OR: 28.81, 95% CI:3.779-219.697, p = 0.001). Crude overall mortality was higher in the leukapheresis group (44%) than in the standard-therapy group (16%)(p = 0.046). However, the leukapheresis group also had higher admission WBC counts, lower platelet counts, and older age, findings consistent with confounding by indication. The leukapheresis group also had longer PICU stays and a higher incidence of hypocalcemia and other complications.
CONCLUSIONS: In this retrospective cohort, leukapheresis effectively reduced the white blood cells but was not independently associated with a lower incidence of TLS or AKI.The higher crude mortality in the leukapheresis arm likely reflects baseline disease severity rather than a direct treatment effect.